DIN 02493020 — TARO-DOXORUBICIN LIPOSOMAL 2 MG
TARO-DOXORUBICIN LIPOSOMAL is a suspension of Doxorubicin marketed by TARO PHARMACEUTICALS INC. The full Doxorubicin monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02493020
- Brand name
- TARO-DOXORUBICIN LIPOSOMAL
- Active ingredient
- Doxorubicin
- Strength
- 2 MG
- Dosage form
- SUSPENSION
- Route
- INTRAVENOUS
- Manufacturer
- TARO PHARMACEUTICALS INC
- Health Canada status
- MARKETED
- Drug class
- Anthracycline antineoplastic (cytotoxic) agent
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Doxorubicin products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02071002 | ADRIAMYCIN PFS | 2 MG | SOLUTION | PFIZER CANADA ULC | DORMANT |
| 02238389 | CAELYX | 2 MG | SUSPENSION | BAXTER CORPORATION | MARKETED |
| 02410397 | DOXORUBICIN | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED |
| 02194473 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED |
| 02194465 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 50 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED |
| 02409275 | DOXORUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED |
| 02413973 | DOXORUBICIN HYDROCHLORIDE INJECTION, USP | 2 MG | SOLUTION | STRIDES PHARMA CANADA INC | DORMANT |
| 02381982 | DOXORUBICIN INJECTION, BP | 2 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED |
| 02245015 | MYOCET | 2 MG | LIPOSOMES | SOPHERION THERAPEUTICS LLC | DORMANT |